Patents Assigned to Lubris LLC
-
Patent number: 11752194Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.Type: GrantFiled: March 9, 2021Date of Patent: September 12, 2023Assignee: Lubris LLCInventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
-
Patent number: 11717557Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.Type: GrantFiled: March 8, 2021Date of Patent: August 8, 2023Assignees: Lubris LLC, Rhode Island HospitalInventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed, Joanna Szmydynger-Chodobska, Adam Chodobski
-
Patent number: 11666529Abstract: Disclosed are methods involving the therapeutic use of human PRG4 (lubricin) protein, to improve vision, to reduce aberrations such as impaired night vision, halos, and glare, to improve the stability of the tear film, and to homogenize the refractive index of the surface of the eye.Type: GrantFiled: May 19, 2016Date of Patent: June 6, 2023Assignee: Lubris LLCInventors: Benjamin D. Sullivan, Edward R. Truitt, III
-
Patent number: 11485764Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.Type: GrantFiled: June 18, 2020Date of Patent: November 1, 2022Assignee: Lubris LLCInventors: Tannin A. Schmidt, Gregory D. Jay
-
Patent number: 11213566Abstract: Provided herein is a pharmaceutical or oral care product for treating or preventing oral diseases that is prepared with proteoglycan 4 (PRG4) as an active ingredient, the preparing method thereof and the use thereof in manufacturing medicaments or oral care products for treating or preventing oral diseases and maintenance of oral health. PRG4 may have efficacy in maintaining oral health and treating or preventing oral disease. This secreted glycoprotein, which is also called lubricin and superficial zone protein, is known to protect against frictional forces, cell adhesion and protein deposition.Type: GrantFiled: January 19, 2011Date of Patent: January 4, 2022Assignee: LUBRIS LLCInventors: Edward R. Truitt, III, Benjamin Sullivan, Nicholas Tennison
-
Patent number: 10967048Abstract: Disclosed herein are methods of using PRG4 glycoprotein, also known as lubricin, to reduce, inhibit, or down-regulate pro-inflammatory pathways in patients at risk of or suffering from an inflammatory response or allergy symptom through CD44 antagonization, regulating pro-inflammatory cytokine production, inhibiting NF-?B translocation and/or facilitating removal of inflammation-inducing cellular or matrix debris or allergens.Type: GrantFiled: January 26, 2016Date of Patent: April 6, 2021Assignee: Lubris LLCInventors: Gregory D. Jay, Benjamin D. Sullivan, Tannin Avery Schmidt, Khaled Elsaid, Edward R. Truitt, Roman Krawetz, Jawed Fareed
-
Patent number: 10960047Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.Type: GrantFiled: November 21, 2019Date of Patent: March 30, 2021Assignee: Lubris LLCInventors: Gregory D. Jay, Tannin A. Schmidt, Benjamin D. Sullivan
-
Patent number: 10723773Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.Type: GrantFiled: November 7, 2018Date of Patent: July 28, 2020Assignee: Lubris LLCInventors: Tannin A. Schmidt, Gregory D. Jay
-
Patent number: 10500251Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.Type: GrantFiled: August 22, 2018Date of Patent: December 10, 2019Assignee: Lubris LLCInventors: Gregory D. Jay, Tannin Schmidt, Benjamin Sullivan
-
Patent number: 10500250Abstract: Disclosed are compositions and methods involving the use of PRG4 protein, also known as lubricin, to mechanically inhibit biological processes involving cell motility and adhesion. The methods and compositions may be used to develop a variety of specific therapies and compositions, often exploited through surgical procedures, where development of the pathology involves one or more of the following modes of action: 1) the passage of cells from one body compartment to another, 2) adherence of macrophages to substrates such as fibrin or exposed extra cellular matrix, 3) binding of platelets to fibrin, or 4) failure of function of the glycocalyx on exposed epithelial cell surfaces, e.g., within the vasculature.Type: GrantFiled: November 25, 2014Date of Patent: December 10, 2019Assignee: Lubris LLCInventors: Gregory D. Jay, Tannin Schmidt, Benjamin Sullivan
-
Patent number: 10383796Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.Type: GrantFiled: August 14, 2017Date of Patent: August 20, 2019Assignee: Lubris LLCInventors: Edward R. Truitt, Nicole Barbara Justis Truitt
-
Patent number: 10125180Abstract: Disclosed are new recombinant isoforms of human-like lubricin or PRG4 glycoprotein having outstanding lubrication properties and a novel glycosylation pattern, and methods for their manufacture at high levels enabling commercial production.Type: GrantFiled: October 22, 2014Date of Patent: November 13, 2018Assignee: Lubris LLCInventors: Tannin A. Schmidt, Gregory D. Jay
-
Patent number: 9982027Abstract: Disclosed are mixed solutions of PRG4 and hyaluronic acids having controlled, enhanced rheological properties adapted for various particular medical and cosmetic uses. Such solutions combine the solution-based lubrication ability of HA and the boundary-based lubricating effects of lubricin. Being more viscous, the solutions when used for joint viscosupplementation enhance both the duration of the HA within the joint capsule (in vivo half-life) and enhance the cushioning effects of the HA, as well as improve both solution and boundary mode lubrication mechanisms.Type: GrantFiled: August 22, 2014Date of Patent: May 29, 2018Assignee: Lubris LLCInventor: Tannin Avery Schmidt
-
Patent number: 9730865Abstract: The present invention relates to the uses of the protein PRG4 and therapeutic modulation thereof. In particular, the present invention relates compositions and methods utilizing PRG4 and therapeutic modulation thereof, including, use as a surgical lubricant, use in a treatment for prevention or reduction of post-surgical adhesions, use in a treatment for oral ulcerations, use as an athletic lubricating patch, use as a dermal filler, use in a treatment for dry mouth, use in a drug delivery method or composition, and use in nursing lubrication.Type: GrantFiled: May 24, 2010Date of Patent: August 15, 2017Assignees: Lubris, LLC, Schepens Eye Research InstituteInventors: Benjamin Sullivan, Edward R. Truitt, David Sullivan
-
Publication number: 20160250286Abstract: Disclosed are mixed solutions of PRG4 and hyaluronic acids having controlled, enhanced rheological properties adapted for various particular medical and cosmetic uses. Such solutions combine the solution-based lubrication ability of HA and the boundary-based lubricating effects of lubricin. Being more viscous, the solutions when used for joint viscosupplementation enhance both the duration of the HA within the joint capsule (in vivo half-life) and enhance the cushioning effects of the HA, as well as improve both solution and boundary mode lubrication mechanisms.Type: ApplicationFiled: August 22, 2014Publication date: September 1, 2016Applicant: LUBRIS, LLCInventor: Tannin Avery Schmidt
-
Patent number: 9107885Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients via administration of a therapeutically effective concentration of PRG4.Type: GrantFiled: August 12, 2010Date of Patent: August 18, 2015Assignee: LUBRIS LLCInventors: Benjamin David Sullivan, Edward R. Truitt, III
-
Patent number: 8980840Abstract: The present invention relates to the management of vaginal health. In particular, the present invention relates to pharmaceutical compositions, and methods of use thereof, for treating diseases associated with compromised boundary lubrication at the vaginal epithelium.Type: GrantFiled: January 13, 2010Date of Patent: March 17, 2015Assignees: Schepens Eye Research Institute, Lubris LLCInventors: Edward R. Truitt, III, Benjamin Sullivan, David Sullivan